AT 101 - IngenOx Therapeutics
Alternative Names: AT-101 IngenOx TherapeuticsLatest Information Update: 13 Jul 2023
At a glance
- Originator Argonaut Therapeutics
- Developer IngenOx Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action PRMT5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 13 Jul 2023 IngenOx Therapeutics plans a phase I JASON trial for Solid tumour (IngenOx Therapeutics pipeline, July 2023)
- 01 May 2023 IngenOX has patent protection for AT 101 in Singapore
- 09 Jan 2023 Argonaut Therapeutics has patent protection for new chemical entities against the drug target protein arginine methyltransferase 5 (PRMT5) (Argonaut Therapeutics website, January 2023).